 | • レポートコード：MRC23Q36206 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、81ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥406,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥812,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の壊死性自己免疫性筋炎市場について調査・分析し、世界の壊死性自己免疫性筋炎市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（ステロイド剤、免疫抑制剤、その他）、用途別セグメント分析（病院、薬局、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、GlaxoSmithKline plc、Dr. Reddy's Laboratories、Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)、Hetero Drugs Limited、AbbVie Inc.、Teva Pharmaceutical Industries、Novartis AGなどが含まれています。世界の壊死性自己免疫性筋炎市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、壊死性自己免疫性筋炎市場規模を推定する際に考慮しました。本レポートは、壊死性自己免疫性筋炎の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、壊死性自己免疫性筋炎に関するビジネス上の意思決定に役立てることを目的としています。 ・壊死性自己免疫性筋炎市場の概要 - 壊死性自己免疫性筋炎のタイプ別セグメント - 世界の壊死性自己免疫性筋炎市場規模：タイプ別分析（ステロイド剤、免疫抑制剤、その他） - 壊死性自己免疫性筋炎の用途別セグメント - 世界の壊死性自己免疫性筋炎市場規模：用途別分析（病院、薬局、その他） - 世界の壊死性自己免疫性筋炎市場規模予測（2018年-2029年） ・壊死性自己免疫性筋炎市場の成長トレンド - 壊死性自己免疫性筋炎の地域別市場規模（2018年-2029年） - 壊死性自己免疫性筋炎市場ダイナミクス - 壊死性自己免疫性筋炎の業界動向 - 壊死性自己免疫性筋炎市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：ステロイド剤、免疫抑制剤、その他 - 世界の壊死性自己免疫性筋炎のタイプ別市場規模（2018年-2023年） - 世界の壊死性自己免疫性筋炎のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、薬局、その他 - 世界の壊死性自己免疫性筋炎の用途別市場規模（2018年-2023年） - 世界の壊死性自己免疫性筋炎の用途別市場規模（2024年-2029年） ・壊死性自己免疫性筋炎の地域別市場規模 - 北米の壊死性自己免疫性筋炎市場規模（2018年-2029年） - アメリカの壊死性自己免疫性筋炎市場規模（2018年-2029年） - ヨーロッパの壊死性自己免疫性筋炎市場規模（2018年-2029年） - アジア太平洋の壊死性自己免疫性筋炎市場規模（2018年-2029年） - 中国の壊死性自己免疫性筋炎市場規模（2018年-2029年） - 日本の壊死性自己免疫性筋炎市場規模（2018年-2029年） - 韓国の壊死性自己免疫性筋炎市場規模（2018年-2029年） - インドの壊死性自己免疫性筋炎市場規模（2018年-2029年） - オーストラリアの壊死性自己免疫性筋炎市場規模（2018年-2029年） - 中南米の壊死性自己免疫性筋炎市場規模（2018年-2029年） - 中東・アフリカの壊死性自己免疫性筋炎市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 GlaxoSmithKline plc、Dr. Reddy's Laboratories、Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)、Hetero Drugs Limited、AbbVie Inc.、Teva Pharmaceutical Industries、Novartis AG ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Necrotizing Autoimmune Myositis market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Necrotizing Autoimmune Myositis is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Necrotizing Autoimmune Myositis is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Necrotizing Autoimmune Myositis in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Necrotizing Autoimmune Myositis include GlaxoSmithKline plc, Dr. Reddy’s Laboratories, Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.), Hetero Drugs Limited, AbbVie Inc., Teva Pharmaceutical Industries and Novartis AG, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Necrotizing Autoimmune Myositis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Necrotizing Autoimmune Myositis.
The Necrotizing Autoimmune Myositis market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Necrotizing Autoimmune Myositis market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Necrotizing Autoimmune Myositis companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
GlaxoSmithKline plc
Dr. Reddy’s Laboratories
Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
Hetero Drugs Limited
AbbVie Inc.
Teva Pharmaceutical Industries
Novartis AG
Segment by Type
Steroid Drugs
Immunosuppressant
Others
Segment by Application
Hospital
Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Necrotizing Autoimmune Myositis companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Necrotizing Autoimmune Myositis Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Steroid Drugs
1.2.3 Immunosuppressant
1.2.4 Others
1.3 Market by Application
1.3.1 Global Necrotizing Autoimmune Myositis Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Necrotizing Autoimmune Myositis Market Perspective (2018-2029)
2.2 Necrotizing Autoimmune Myositis Growth Trends by Region
2.2.1 Global Necrotizing Autoimmune Myositis Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Necrotizing Autoimmune Myositis Historic Market Size by Region (2018-2023)
2.2.3 Necrotizing Autoimmune Myositis Forecasted Market Size by Region (2024-2029)
2.3 Necrotizing Autoimmune Myositis Market Dynamics
2.3.1 Necrotizing Autoimmune Myositis Industry Trends
2.3.2 Necrotizing Autoimmune Myositis Market Drivers
2.3.3 Necrotizing Autoimmune Myositis Market Challenges
2.3.4 Necrotizing Autoimmune Myositis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Necrotizing Autoimmune Myositis Players by Revenue
3.1.1 Global Top Necrotizing Autoimmune Myositis Players by Revenue (2018-2023)
3.1.2 Global Necrotizing Autoimmune Myositis Revenue Market Share by Players (2018-2023)
3.2 Global Necrotizing Autoimmune Myositis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Necrotizing Autoimmune Myositis Revenue
3.4 Global Necrotizing Autoimmune Myositis Market Concentration Ratio
3.4.1 Global Necrotizing Autoimmune Myositis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Necrotizing Autoimmune Myositis Revenue in 2022
3.5 Necrotizing Autoimmune Myositis Key Players Head office and Area Served
3.6 Key Players Necrotizing Autoimmune Myositis Product Solution and Service
3.7 Date of Enter into Necrotizing Autoimmune Myositis Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Necrotizing Autoimmune Myositis Breakdown Data by Type
4.1 Global Necrotizing Autoimmune Myositis Historic Market Size by Type (2018-2023)
4.2 Global Necrotizing Autoimmune Myositis Forecasted Market Size by Type (2024-2029)
5 Necrotizing Autoimmune Myositis Breakdown Data by Application
5.1 Global Necrotizing Autoimmune Myositis Historic Market Size by Application (2018-2023)
5.2 Global Necrotizing Autoimmune Myositis Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Necrotizing Autoimmune Myositis Market Size (2018-2029)
6.2 North America Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Necrotizing Autoimmune Myositis Market Size by Country (2018-2023)
6.4 North America Necrotizing Autoimmune Myositis Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Necrotizing Autoimmune Myositis Market Size (2018-2029)
7.2 Europe Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Necrotizing Autoimmune Myositis Market Size by Country (2018-2023)
7.4 Europe Necrotizing Autoimmune Myositis Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Necrotizing Autoimmune Myositis Market Size (2018-2029)
8.2 Asia-Pacific Necrotizing Autoimmune Myositis Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Necrotizing Autoimmune Myositis Market Size by Region (2018-2023)
8.4 Asia-Pacific Necrotizing Autoimmune Myositis Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Necrotizing Autoimmune Myositis Market Size (2018-2029)
9.2 Latin America Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Necrotizing Autoimmune Myositis Market Size by Country (2018-2023)
9.4 Latin America Necrotizing Autoimmune Myositis Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Necrotizing Autoimmune Myositis Market Size (2018-2029)
10.2 Middle East & Africa Necrotizing Autoimmune Myositis Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Necrotizing Autoimmune Myositis Market Size by Country (2018-2023)
10.4 Middle East & Africa Necrotizing Autoimmune Myositis Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline plc
11.1.1 GlaxoSmithKline plc Company Detail
11.1.2 GlaxoSmithKline plc Business Overview
11.1.3 GlaxoSmithKline plc Necrotizing Autoimmune Myositis Introduction
11.1.4 GlaxoSmithKline plc Revenue in Necrotizing Autoimmune Myositis Business (2018-2023)
11.1.5 GlaxoSmithKline plc Recent Development
11.2 Dr. Reddy’s Laboratories
11.2.1 Dr. Reddy’s Laboratories Company Detail
11.2.2 Dr. Reddy’s Laboratories Business Overview
11.2.3 Dr. Reddy’s Laboratories Necrotizing Autoimmune Myositis Introduction
11.2.4 Dr. Reddy’s Laboratories Revenue in Necrotizing Autoimmune Myositis Business (2018-2023)
11.2.5 Dr. Reddy’s Laboratories Recent Development
11.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
11.3.1 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Detail
11.3.2 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Business Overview
11.3.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Necrotizing Autoimmune Myositis Introduction
11.3.4 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Revenue in Necrotizing Autoimmune Myositis Business (2018-2023)
11.3.5 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Recent Development
11.4 Hetero Drugs Limited
11.4.1 Hetero Drugs Limited Company Detail
11.4.2 Hetero Drugs Limited Business Overview
11.4.3 Hetero Drugs Limited Necrotizing Autoimmune Myositis Introduction
11.4.4 Hetero Drugs Limited Revenue in Necrotizing Autoimmune Myositis Business (2018-2023)
11.4.5 Hetero Drugs Limited Recent Development
11.5 AbbVie Inc.
11.5.1 AbbVie Inc. Company Detail
11.5.2 AbbVie Inc. Business Overview
11.5.3 AbbVie Inc. Necrotizing Autoimmune Myositis Introduction
11.5.4 AbbVie Inc. Revenue in Necrotizing Autoimmune Myositis Business (2018-2023)
11.5.5 AbbVie Inc. Recent Development
11.6 Teva Pharmaceutical Industries
11.6.1 Teva Pharmaceutical Industries Company Detail
11.6.2 Teva Pharmaceutical Industries Business Overview
11.6.3 Teva Pharmaceutical Industries Necrotizing Autoimmune Myositis Introduction
11.6.4 Teva Pharmaceutical Industries Revenue in Necrotizing Autoimmune Myositis Business (2018-2023)
11.6.5 Teva Pharmaceutical Industries Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Detail
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Necrotizing Autoimmune Myositis Introduction
11.7.4 Novartis AG Revenue in Necrotizing Autoimmune Myositis Business (2018-2023)
11.7.5 Novartis AG Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details